Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial

BackgroundBK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to aluminium hydroxide gel and reconstituted, prior to administration, with synthetic oligodeoxynucleotides bearing CpG motifs. In health...

Descrición completa

Detalles Bibliográficos

Principais autores:	Alphonse Ouédraogo, Edith Christiane Bougouma, Nirianne Marie Q. Palacpac, Sophie Houard, Issa Nebie, Jean Sawadogo, Gloria D. Berges, Issiaka Soulama, Amidou Diarra, Denise Hien, Amidou Z. Ouedraogo, Amadou T. Konaté, Seni Kouanda, Akira Myoui, Sachiko Ezoe, Ken J. Ishii, Takanobu Sato, Flavia D’Alessio, Odile Leroy, Alfred B. Tiono, Simon Cousens, Toshihiro Horii, Sodiomon B. Sirima
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2023-10-01
Series:	Frontiers in Immunology
Assuntos:	BK-SE36/CpG malaria vaccine Plasmodium falciparum serine repeat antigen SERA5 safety
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267372/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!